InnoCare Pharma Limited Just Missed Revenue By 19%: Here’s What Analysts Think Will Happen Next

Last week, you might have seen that InnoCare Pharma Limited (HKG:9969) released its first-quarter result to the market. The early response was not positive, with shares down 6.5% to HK$14.70 in the past week. Revenues were CN¥529m, 19% below analyst expectations, although losses didn’t appear to worsen significantly, with a statutory per-share loss of CN¥0.38 being in line with what the analysts anticipated. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10bn in marketcap – there is still time to get in early.

Taking into account the latest results, InnoCare Pharma’s nine analysts currently expect revenues in 2026 to be CN¥2.52b, approximately in line with the last 12 months. Statutory earnings per share are forecast to tumble 90% to CN¥0.042 in the same period. Before this earnings report, the analysts had been forecasting revenues of CN¥2.32b and earnings per share (EPS) of CN¥0.091 in 2026. While next year’s revenue estimates increased, there was also a pretty serious reduction to EPS expectations, suggesting the consensus has a bit of a mixed view of these results.

Check out our latest analysis for InnoCare Pharma

The consensus price target fell 5.7% to HK$20.07, suggesting that the analysts are primarily focused on earnings as the driver of value for this business. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values InnoCare Pharma at HK$22.14 per share, while the most bearish prices it at HK$17.38. The narrow spread of estimates could suggest that the business’ future is relatively easy to value, or thatthe analysts have a strong view on its prospects.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We would highlight that InnoCare Pharma’s revenue growth is expected to slow, with the forecast 0.07% annualised growth rate until the end of 2026 being well below the historical 28% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 23% per year. Factoring in the forecast slowdown in growth, it seems obvious that InnoCare Pharma is also expected to grow slower than other industry participants.

The Bottom Line

The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Fortunately, they also upgraded their revenue estimates, although our data indicates it is expected to perform worse than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of InnoCare Pharma’s future valuation.

With that in mind, we wouldn’t be too quick to come to a conclusion on InnoCare Pharma. Long-term earnings power is much more important than next year’s profits. At Simply Wall St, we have a full range of analyst estimates for InnoCare Pharma going out to 2028, and you can see them free on our platform here..

We don’t want to rain on the parade too much, but we did also find 2 warning signs for InnoCare Pharma that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.